Hypotonic Treprostinil Subcutaneous Infusion for Control of Treprostinil Related Site Pain

• Status: Withdrawn
• Trial end date: 2019-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The investigators will test whether hypotonic (diluted) remodulin solution causes less pain than the eutonic (undiluted) solution supplied by the manufacturer.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Jewish General Hospital
• Treatments: Pharmaceutical Solutions; Treprostinil

Criteria

Inclusion Criteria:

• PAH by standard criteria

• Treatment with subcutaneous remodulin infusion for at least 3 months, with stable dose for 1 month

• Pain at infusion site (defined as > 8 on McGill Pain Questionnaire)

Exclusion Criteria:

• Known pregnancy or breastfeeding